SPRB
SPRUCE BIOSCIENCES, INC.
$49.32
-2.20%
$134.9M
No data for this timeframe.
Vol
Market Cap$134.9M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders3 funds
Inst. Value$1.6M
Inst. Activity3 buys / 0 sells
SEC Reports4
Recent Activity
May 21, 2026
Insider
SPIEGELMAN DANIEL K sold 1,700 shares
Director @ $0.00 ($0.00)
May 21, 2026
Insider
GREY MICHAEL G sold 1,700 shares
Executive Chairman @ $0.00 ($0.00)
May 21, 2026
Insider
Barretto-Ko Percival sold 1,700 shares
Director @ $0.00 ($0.00)
May 13, 2026
SEC
Spruce Biosciences reported Q1 2026 net loss of $12.3M ($(8.94)/share), missing consensus EPS of $(7.32) by 22%. Cash an
8-K — Impact 5/10
May 13, 2026
earnings_calendar
SPRB Q1 2026 Earnings After Market Close — 2026-05-13
Apr 21, 2026
SEC
Spruce Biosciences is raising $59.9 million through a public offering of 1.15 million shares and pre-funded warrants for
424B5 — Impact 5/10
Apr 20, 2026
SEC
Spruce Biosciences is conducting a public offering of common stock and pre-funded warrants to raise capital, with net pr
424B5 — Impact 5/10
Inst.
VANGUARD GROUP INC — NEW
17,873 shares ($1.6M)
Price Targets
$154.17
+214.4% upside
Strong Buy
Current $49.03
Low $120.00
Median $145.00
High $230.00
6 analysts
$120.00
$230.00
Analyst Ratings
4Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 9, 2026 | Jones Trading | INITIATE | Buy |
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Apr 27, 2026 | Craig-Hallum | INITIATE | Buy |
| Mar 10, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-5.82 ▼ -1.7% | $-8.18 — $-4.38 | 5 | |
| Next Q | $-4.98 ▲ +20.0% | $-5.24 — $-4.62 | 66% YoY | 5 |
| Current FY | $-24.11 ▲ +1.7% | $-28.73 — $-22.16 | 53% YoY | 5 |
| Next FY | $9.27 ▲ +115.6% | $-19.26 — $38.85 | 138% YoY | 5 |
Latest Reports
MIXED
8-K
5/10
Spruce Biosciences reported Q1 2026 net loss of $12.3M ($(8.94)/share), missing consensus EPS of $(7.32) by 22%. Cash an
May 13, 2026
NEUTRAL
424B5
5/10
Spruce Biosciences is raising $59.9 million through a public offering of 1.15 million shares and pre-funded warrants for
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.6M | NEW |
| MORGAN STANLEY | $33.8K | DOUBLED |
| BANK OF AMERICA CORP | $8.1K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | SPIEGELMAN DANIEL | A | $0.00 |
| May 21, 2026 | GREY MICHAEL | A | $0.00 |
| May 21, 2026 | Barretto-Ko Percival | A | $0.00 |
| May 21, 2026 | SIMPSON CAMILLA | A | $0.00 |
| May 21, 2026 | Walbert Keli | A | $0.00 |
3 institutional holders with $1.6M total value (18,354 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 17,873 | $1.6M | 97.4% | NEW |
| 2 | MORGAN STANLEY | 388 | $33.8K | 2.1% | DOUBLED +295.9% |
| 3 | BANK OF AMERICA CORP /DE/ | 93 | $8.1K | 0.5% | DOUBLED +3000.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | NEW | — | 17,873 | — | $1.6M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 98 | 388 | +295.9% | $33.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 3 | 93 | +3000.0% | $8.1K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 382,900 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | EXIT | 843,844 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | EXIT | 116,464 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | ADD | 86,045 | 116,464 | +35.4% | $33.8K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 2,133 | 7,396 | +246.7% | $2.1K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 609,700 | 405,900 | -33.4% | $170.5K | 2024-Q4 |
| UBS Group AG | DOUBLED | 13 | 86,045 | +661784.6% | $36.1K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 80,353 | 0 | -100.0% | $0.00 | 2024-Q4 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | SPIEGELMAN DANIEL K | Director | A | 1,700 | $0.00 | $0.00 |
| May 21, 2026 | GREY MICHAEL G | Executive Chairman | A | 1,700 | $0.00 | $0.00 |
| May 21, 2026 | Barretto-Ko Percival | Director | A | 1,700 | $0.00 | $0.00 |
| May 21, 2026 | SIMPSON CAMILLA V | Director | A | 1,700 | $0.00 | $0.00 |
| May 21, 2026 | Walbert Keli | Director | A | 1,700 | $0.00 | $0.00 |
| Mar 9, 2026 | Hooks Corwin Dale | Chief Commercial Officer | A | 11,000 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 2 neutral. Avg impact: 5.3/10.
MIXED
8-K
5/10
Spruce Biosciences reported Q1 2026 net loss of $12.3M ($(8.94)/share), missing consensus EPS of $(7
May 13, 2026
NEUTRAL
424B5
5/10
Spruce Biosciences is raising $59.9 million through a public offering of 1.15 million shares and pre
Apr 21, 2026
NEUTRAL
424B5
5/10
Spruce Biosciences is conducting a public offering of common stock and pre-funded warrants to raise
Apr 20, 2026
MIXED
8-K
6/10
Spruce Biosciences entered into an at-the-market (ATM) equity offering agreement with Jefferies to s
Mar 9, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 4 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$154.17 mean target
+214.4% upside
Strong Buy (1.17)
$120.00 Low
$230.00 High
| Metric | Value |
|---|---|
| Current Price | $49.03 |
| Target Low | $120.00 |
| Target Mean | $154.17 |
| Target Median | $145.00 |
| Target High | $230.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.17) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-5.82 | $-8.18 | $-4.38 | — | -1.7% | 2↑ 1↓ | $0.0B | 0.0% | 5 |
| Next Q 2026-09-30 |
$-4.98 | $-5.24 | $-4.62 | 65.8% | +20.0% | 2↑ 1↓ | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-24.11 | $-28.73 | $-22.16 | 52.6% | +1.7% | 1↑ 2↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$9.27 | $-19.26 | $38.85 | 138.5% | +115.6% | 0↑ 3↓ | $0.1B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-5.822 | |
| 7d ago | $-5.232 | -0.590 |
| 30d ago | $-5.723 | -0.099 |
| 60d ago | $-6.433 | +0.611 |
| 90d ago | $-6.433 | +0.611 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 9, 2026 | Jones Trading | INITIATE | — | Buy |
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 27, 2026 | Craig-Hallum | INITIATE | — | Buy |
| Mar 10, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 23, 2025 | Oppenheimer | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Jan 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
SPRB Q1 2026 Earnings After Market Close — 2026-05-13
May 11, 2026
earnings_calendar
SPRB Q1 2026 Earnings After Market Close — 2026-05-11
May 4, 2026
earnings_calendar
SPRB Q1 2026 Earnings After Market Close — 2026-05-04
Apr 17, 2026
short_interest
FTD: SPRB — 8,379 shares ($0.6M) failed to deliver
Settlement: 20260417, Price: $67.90, FTD Value: $568,934.1, SPRUCE BIOSCIENCES INC
Apr 16, 2026
short_interest
FTD: SPRB — 25,009 shares ($1.7M) failed to deliver
Settlement: 20260416, Price: $69.32, FTD Value: $1,733,623.88, SPRUCE BIOSCIENCES INC
Apr 15, 2026
short_interest
FTD: SPRB — 24,874 shares ($1.7M) failed to deliver
Settlement: 20260415, Price: $67.80, FTD Value: $1,686,457.2, SPRUCE BIOSCIENCES INC
Apr 14, 2026
short_interest
FTD: SPRB — 24,874 shares ($1.6M) failed to deliver
Settlement: 20260414, Price: $64.51, FTD Value: $1,604,621.74, SPRUCE BIOSCIENCES INC
Apr 13, 2026
short_interest
FTD: SPRB — 19,258 shares ($1.2M) failed to deliver
Settlement: 20260413, Price: $63.63, FTD Value: $1,225,386.54, SPRUCE BIOSCIENCES INC
Apr 10, 2026
short_interest
FTD: SPRB — 14,569 shares ($1.0M) failed to deliver
Settlement: 20260410, Price: $66.01, FTD Value: $961,699.69, SPRUCE BIOSCIENCES INC
Apr 9, 2026
short_interest
FTD: SPRB — 10,263 shares ($0.7M) failed to deliver
Settlement: 20260409, Price: $63.65, FTD Value: $653,239.95, SPRUCE BIOSCIENCES INC